Kura Oncology, Inc. (NASDAQ:KURA) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET
Company Participants
Pete De Spain - Head, IR
Troy Wilson - President and CEO
Thomas Doyle - SVP of Finance and Accounting
Conference Call Participants
Li Watsek - Cantor Fitzgerald
Jonathan Chang - Leerink Partners
Cameron Bozdog - Bank of America
Roger Song - Jefferies
Brad Canino - Stifel
Phil Nadeau - TD Cowen
Alex Bouilloux - Barclays
Justin Zelin - BTIG
George Farmer - Scotiabank
Operator
Good day, and welcome to the Q2 2024 Kura Oncology Conference Call. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Pete De Spain, Head of Investor Relations. Please go ahead.
Pete De Spain
Great. Thank you, Amy. Good afternoon, and welcome to Kura Oncology's second quarter 2024 conference call. Joining me on the call are Dr. Troy Wilson, our President and CEO, and Tom Doyle, our Senior Vice President of Finance and Accounting.
Before I turn the call over to Troy, I'd like to remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from expected results. Please refer to Kura's filings with the SEC, which are available from the SEC or on the Kura Oncology website for information concerning risk factors that could affect the company.
With that, I'll turn the call over to Troy.
Troy Wilson
Thank you, Pete. And thank you all for joining us.
This past quarter was highlighted by strong execution across the organization as we continue to generate a robust clinical data package to support broad development of our menin inhibitor program beginning with ziftomenib.
In April, ziftomenib became the first investigational therapy to be granted Breakthrough Therapy Designation for treatment of relapsed/refractory NPM1-mutant acute myeloid leukemia. FDA awarded BTD based on data from our KOMET-001 trial, recognizing ziftomenib's potential as an innovative medicine for patients with this devastating disease.
In May, we announced completion of enrollment in the registration-directed portion of KOMET-001, enrolling more than 85 NPM1-mutant AML patients in fewer than 16 months. We believe this important milestone reinforces ziftomenib's potential best-in-class profile. As a reminder, NPM1-mutant AML represents approximately 30% of new AML cases annually, and is a disease of significant unmet need for which there's no approved targeted therapy.